GlassScriptPhysician profile
Jonathan W Soto
NPI 1831509082
$1,995.00
in general payments reported to CMS, 2019-2025
22 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.36 · 2020: $15.23 · 2021: $95.67 · 2022: $229 · 2023: $263 · 2024: $756 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $368.56 | 2022-2025 | Freestyle Libre 3, Eterna |
| Lilly USA, LLC | $328.28 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $286.25 | 2023-2025 | |
| Exact Sciences Corporation | $218.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.27 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $121.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $70.67 | 2022-2024 | Ubrelvy |
| Sanofi-Aventis U.S. LLC | $69.75 | 2024-2025 | |
| Glaxosmithkline, LLC. | $63.83 | 2021-2025 | Shingrix, Bexsero, Arexvy |
| Dexcom, INC. | $54.15 | 2024-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $49.39 | 2023 | Xarelto |
| Astellas Pharma US INC | $39.12 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $33.26 | 2022-2023 | Dificid |
| Medtronic, INC. | $31.55 | 2023-2024 | Venaseal |
| Sobi, INC | $23.17 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20.94 | 2025 | Breztri |
| Alk-Abello, INC | $17.76 | 2025 | Neffy, Odactra, Grastek |
| Genentech USA, INC. | $15.23 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.65 | 2024 | Quviviq |
| Althera Pharmaceuticals LLC | $13.85 | 2021 | |
| Amarin Pharma, INC. | $12.75 | 2022 | |
| Optinose US, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Soto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.